Jul. 9 at 3:17 PM
$VTGN looks like it could have a chance of it getting through to approval.
The chance of Vistagen's fasedienol getting FDA approval for the acute treatment of social anxiety disorder is difficult to quantify but is considered a high-risk, high-reward opportunity. While fasedienol has received Fast Track designation which could accelerate the process, and Vistagen has shown promising results in Phase 2 and early Phase 3 trials, there's no guarantee of success.
